ResearcherSecond Military Medical UniversityActive in the last 2 years
Yunguang Li
Matched on ORCID iD 0000-0002-2869-8071, 0009-0005-4155-2914; OpenAlex author ID A5018009581. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 3, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 29
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 5 papers · 2026: 2 papers
Papers 9
- The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy. First author DOI 10.1016/j.canlet.2026.218252↗
- Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post- neoadjuvant therapy" [Cancer Lett. (202… First author DOI 10.1016/j.canlet.2026.218298↗
- A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy. Co-author DOI 10.1016/j.stem.2025.07.008↗
- Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
- Clinical functional proteomics of intercellular signalling in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08225-y↗
- ODFormer: a Virtual Organoid for Predicting Personalized Therapeutic Responses in Pancreatic Cancer Co-author DOI 10.1101/2025.07.08.663664↗
- Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.181873↗
- Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101162↗
- Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. First author DOI 10.1038/s41467-022-29857-6↗
Closest collaborators
The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dong Gao · 7 shared papers, 2022–2025 · strength 1.20
- Paper Clinical functional proteomics of intercellular signalling in pancreatic cancer. DOI 10.1038/s41586-024-08225-y↗
- Paper ODFormer: a Virtual Organoid for Predicting Personalized Therapeutic Responses in Pancreatic Cancer DOI 10.1101/2025.07.08.663664↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Xiaohan Shi · 7 shared papers, 2022–2026 · strength 1.20
- Paper ODFormer: a Virtual Organoid for Predicting Personalized Therapeutic Responses in Pancreatic Cancer DOI 10.1101/2025.07.08.663664↗
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Gang Jin · 7 shared papers, 2022–2026 · strength 1.19
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Kailian Zheng · 6 shared papers, 2022–2026 · strength 1.06
- Paper ODFormer: a Virtual Organoid for Predicting Personalized Therapeutic Responses in Pancreatic Cancer DOI 10.1101/2025.07.08.663664↗
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Yehan Zhang · 6 shared papers, 2022–2026 · strength 1.04
- Paper Clinical functional proteomics of intercellular signalling in pancreatic cancer. DOI 10.1038/s41586-024-08225-y↗
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Xiongfei Xu · 5 shared papers, 2022–2026 · strength 0.86
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Shiwei Guo · 5 shared papers, 2022–2025 · strength 0.80
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Paper A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of st… DOI 10.1016/j.stem.2025.07.008↗
- Paper Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. DOI 10.1038/s41467-025-57520-3↗
- Xiaoyi Yin · 4 shared papers, 2025–2026 · strength 0.74
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Lingyu Zhu · 3 shared papers, 2025–2026 · strength 0.58
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Suizhi Gao · 3 shared papers, 2022–2025 · strength 0.47
- Paper Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. DOI 10.1172/jci.insight.181873↗
- Paper Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. DOI 10.1038/s41467-025-57520-3↗
- Paper Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug… DOI 10.1038/s41467-022-29857-6↗
- Meilong Shi · 2 shared papers, 2026 · strength 0.39
- Paper The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant ther… DOI 10.1016/j.canlet.2026.218252↗
- Paper Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-… DOI 10.1016/j.canlet.2026.218298↗
- Yu Shi · 1 shared paper, 2025 · strength 0.20
- Peiwu Huang · 1 shared paper, 2025 · strength 0.20
- Gang Jin · 1 shared paper, 2025 · strength 0.20
- Min Wang · 1 shared paper, 2025 · strength 0.20
- Jing Xu · 1 shared paper, 2025 · strength 0.20
- Tony R. Hunter · 1 shared paper, 2025 · strength 0.20
- Renyi Qin · 1 shared paper, 2025 · strength 0.20
- Ruijun Tian · 1 shared paper, 2025 · strength 0.20
- Huan Wang · 1 shared paper, 2026 · strength 0.20
- Huan Wang · 1 shared paper, 2026 · strength 0.20
- Bo Li · 1 shared paper, 2025 · strength 0.19
- Eric Tran · 1 shared paper, 2025 · strength 0.19
- Chunming Zhang · 1 shared paper, 2025 · strength 0.16
- Bin Song · 1 shared paper, 2025 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.